Overcoming scientific and structural bottlenecks in antibacterial discovery and development

References

• Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–98.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int J Antimicrob Agents. 2012;39:295–9.
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat. 2011;14:118–24.
   PubMed Web of Science ®Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71–109.
   PubMed Web of Science ®Google Scholar
• Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis. 2013;13:269–75.
   PubMed Web of Science ®Google Scholar
• Mossialos E, Morel CM, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research. 2010. Available at http://www.euro.who.int/en/about-us/partners/observatory/studies/policies-and-incentives-for-promoting-innovation-in-antibiotic-research. Accessed 17th december 2013.
   Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6:29–40.
   PubMed Web of Science ®Google Scholar
• So AD, Gupta N, Brahmachari SK, Chopra I, Munos B, Nathan C, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat. 2011;14:88–94.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Outterson K. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals. Health Aff (Millwood). 2010;29:1689–96.
   PubMed Web of Science ®Google Scholar
• Nathan C. Aligning pharmaceutical innovation with medical need. Nat Med. 2007;13:304–8.
   PubMed Web of Science ®Google Scholar
• ReAct. Collaboration for innovation. 2011. Available at http://www.reactgroup.org/uploads/resources/Collaboration-for-Innovation-for-webb.pdf. Accessed 17th december 2013.
   Google Scholar
• So AD, Ruiz-Esparza Q, Gupta N, Cars O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ. 2012;344:e1782.
   PubMedGoogle Scholar
• WHO. Global incidence and prevalence of selected curable sexually transmitted infections. 2008. Available at www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf. Accessed 17th december 2013.
   Google Scholar
• Swedish Government. Innovative incentives for effective antibacterials. 2009. Available at http://www.reactgroup.org/uploads/what-we-do/innovative-incentives-for-effective-antibacterials.pdf. Accessed 17th december 2013.
   Google Scholar
• Council of the European Union. Council Conclusions on innovative incentives for effective antibiotics. 2009. Available at http://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/111608.pdf. Accessed 17th december 2013.
   Google Scholar
• European Commission. Communication from the Commission to the European Parliament and the Council Action plan against the rising threats from antimicrobial resistance. 2011. Available at http://ec.europa.eu/dgs/health_consumer/docs/communication_amr_2011_748_en.pdf. Accessed 17th december 2013.
   Google Scholar
• Bergstrom R. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance. Drug Resist Updat. 2011;14:77–8.
   Google Scholar
• Sams-Dodd F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov Today. 2013;18:211–17.
   PubMed Web of Science ®Google Scholar
• White RJ. The early history of antibiotic discovery: empiricism ruled. In Dougherty TJ, Pucci MJ, editors. Antibiotic discovery and development. Springer; 2012.
   Google Scholar
• Innovative Medicines Initiative. 2012. Available at http://www.imi.europa.eu/sites/default/files/uploads/documents/6th_Call/1_Annex%201%20%206th%20Call%20for%20Proposals_2012%2005%2024.pdf. Accessed 17th december 2013.
   Google Scholar
• Roy A, McDonald PR, Sittampalam S, Chaguturu R. Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Curr Pharm Biotechnol. 2010;11:764–78.
   PubMed Web of Science ®Google Scholar
• Manchester JI, Buurman ET, Bisacchi GS, McLaughlin RE. Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery. J Med Chem. 2012;55:2532–7.
   PubMed Web of Science ®Google Scholar
• Silver LL. Antibacterial discovery: problems and possibilities. In Gualerzi C, Brandi L, Fabbretti A, Pon CL, editors. Antibiotics: targets, mechanisms and resistance. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2013.
   Google Scholar
• Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012;10:243–54.
   PubMed Web of Science ®Google Scholar
• Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect. 2008;38:426–30.
   PubMed Web of Science ®Google Scholar
• Fernebro J. Fighting bacterial infections—future treatment options. Drug Resist Updat. 2011;14:125–39.
   PubMed Web of Science ®Google Scholar
• VINNOVA. Bad Bugs—Future Drugs? 2009. Available at http://www.vinnova.se/upload/Bad%20Bugs%20Future%20drugs.pdf. Accessed 17th december 2013.
   Google Scholar
• Hrabak J, Chudackova E, Walkova R. Matrix-assisted laser desorption ionization-time of flight (maldi-tof) mass spectrometry for detection of antibiotic resistance mechanisms: from research to routine diagnosis. Clin Microbiol Rev. 2013;26:103–14.
   PubMed Web of Science ®Google Scholar
• O’Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem. 2008;51:2871–8.
   PubMed Web of Science ®Google Scholar
• Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J, et al. Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. ChemMedChem. 2008;3:435–44.
   PubMed Web of Science ®Google Scholar
• Singh SB, Young K, Miesel L. Screening strategies for discovery of antibacterial natural products. Expert Rev Anti Infect Ther. 2011;9:589–613.
   PubMed Web of Science ®Google Scholar